SCHEMBL3352532

SCHEMBL3352532

COC(=O)c1ccc([N+](=O)[O-])c(OS(=O)(=O)C(F)(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
VCAM1 P19320 1/20 0.54
ALDH1A1 P00352 5/20 0.50
HPGD P15428 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
AR P10275 1/20 0.47
PELP1 Q8IZL8 1/20 0.47
PKM P14618 1/20 0.46
NOTUM Q6P988 1/20 0.45
POLB P06746 1/20 0.45
MAPT P10636 3/20 0.44
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
KMT2A Q03164 2/20 0.42
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MYC P01106 1/20 0.42
MAX P61244 1/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8767362 0.94 VCAM1 (0.49) VCAM1ALDH1A1HPGDNPSR1AR
SCHEMBL2484778 0.93 VCAM1 (0.57) VCAM1ALDH1A1HPGDNPSR1PKM
SCHEMBL8768519 0.90 VCAM1 (0.46) VCAM1ALDH1A1HPGDNPSR1AR
SCHEMBL3354100 0.87 KMT2A (0.53) ALDH1A1PKMPOLBMAPTGAA
SCHEMBL7031271 0.84 VCAM1 (0.63) VCAM1ALDH1A1HPGDNPSR1AR
SCHEMBL31336381 0.83 MAPT (0.57) ALDH1A1HPGDNPSR1PKMNOTUM
SCHEMBL4580602 0.83 MAPT (0.57) ALDH1A1HPGDNPSR1PKMNOTUM
SCHEMBL2934710 0.83 MAPT (0.57) ALDH1A1NPSR1PKMNOTUMMAPT
SCHEMBL31238876 0.83 MAPT (0.57) ALDH1A1NPSR1PKMNOTUMMAPT
SCHEMBL2315350 0.82 LCK (0.43) VCAM1ALDH1A1HPGDNPSR1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9918959-B2 TLR-independent small molecule adjuvants THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-03-20 US disclosed
US-20170224653-A1 TLR-INDEPENDENT SMALL MOLECULE ADJUVANTS THE SCRIPPS RESEARCH INSTITUTE 2017-08-10 US disclosed
US-20170224653-A1 TLR-INDEPENDENT SMALL MOLECULE ADJUVANTS THE SCRIPPS RESEARCH INSTITUTE 2017-08-10 US disclosed
US-9649373-B2 Neoseptins: small molecule adjuvants THE SCRIPPS INSTITUTE (US) 2017-05-16 US disclosed
US-9649373-B2 Neoseptins: small molecule adjuvants THE SCRIPPS INSTITUTE (US) 2017-05-16 US disclosed
EP-2958889-B1 NEOSEPTINS: SMALL MOLECULE ADJUVANTS SCRIPPS RESEARCH INST (US) 2017-03-22 EP disclosed
WO-2016022700-A2 TLR-INDEPENDENT SMALL MOLECULE ADJUVANTS THE SCRIPPS RESEARCH INSTITUTE (US) 2016-02-11 WO disclosed
US-20160000907-A1 NEOSEPTINS: SMALL MOLECULE ADJUVANTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-01-07 US disclosed
US-20160000907-A1 NEOSEPTINS: SMALL MOLECULE ADJUVANTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-01-07 US disclosed
WO-2014131023-A1 NEOSEPTINS: SMALL MOLECULE ADJUVANTS THE SCRIPPS RESEARCH INSTITUTE (US) 2014-08-28 WO disclosed
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed
WO-2006012310-A2 CARBAZOLE DERIVATIVES FOR TREATING POLYCYSTIC KIDNEY DISEASE GENZYME CORPORATION (US) 2006-02-02 WO disclosed
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives PHARMACIA & UPJOHN COMPANY 2004-09-02 US disclosed
US-5872280-A RESPIRATORY SYSTEM DISORDERS BAYER AKTIENGESELLSCHAFT (DE) 1999-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives BACE1, BACE2, PSEN1 VCAM1 3842/4885ALDH1A1 527/4885HPGD 155/4885
US-20160000907-A1 NEOSEPTINS: SMALL MOLECULE ADJUVANTS TLR2, TLR4, TLR1 VCAM1 2113/4885ALDH1A1 4691/4885HPGD 623/4885
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP VCAM1 3540/4885ALDH1A1 2133/4885HPGD 1390/4885
US-20170224653-A1 TLR-INDEPENDENT SMALL MOLECULE ADJUVANTS TLR1, TLR9, TLR3 VCAM1 2755/4885ALDH1A1 4837/4885HPGD 3221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.